Table 2.
Baseline characteristics of study population who had received a complete series with CoronaVac, according to the booster vaccine received
| Overall (n=16 138) | CoronaVac (n=608) | BNT162b2 (n=10 095) | ChAdOx1 (n=5435) | ||
|---|---|---|---|---|---|
| Age, years | |||||
| 18–39 | 4904 (30·4%) | 30 (4·9%) | 4859 (48·1%) | 15 (0·3%) | |
| 40–49 | 2682 (16·6%) | 38 (6·2%) | 2625 (26·0%) | 19 (0·3%) | |
| 50–59 | 2939 (18·2%) | 113 (18·6%) | 1703 (16·9%) | 1123 (20·7%) | |
| ≥60 | 5613 (34·8%) | 427 (70·2%) | 908 (9·0%) | 4278 (78·7%) | |
| Gender | |||||
| Male | 6090 (37·7%) | 211 (34·7%) | 3644 (36·1%) | 2235 (41·1%) | |
| Female | 10 048 (62·3%) | 397 (65·3%) | 6451 (63·9%) | 3200 (58·9%) | |
| Previous positive COVID-19 PCR | 1042 (6·5%) | 43 (7·1%) | 675 (6·7%) | 324 (6·0%) | |
| Previous positive COVID-19 IgG | 476 (2·9%) | 15 (2·5%) | 324 (3·2%) | 137 (2·5%) | |
| Comorbidities | |||||
| Obesity | 837 (5·2%) | 43 (7·1%) | 581 (5·8%) | 213 (3·9%) | |
| High blood pressure | 3667 (22·7%) | 253 (41·6%) | 1298 (12·9%) | 2116 (38·9%) | |
| Diabetes | 1775 (11·0%) | 137 (22·5%) | 640 (6·3%) | 998 (18·4%) | |
| Cancer | 297 (1·8%) | 26 (4·3%) | 169 (1·7%) | 102 (1·9%) | |
| Chronic pulmonary disease | 812 (5·0%) | 41 (6·7%) | 489 (4·8%) | 282 (5·2%) | |
| Chronic cardiovascular disease | 572 (3·5%) | 101 (16·6%) | 227 (2·2%) | 244 (4·5%) | |
Data are n (%)